Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies

Recent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Pascual, Jesus, Ayuso-Sacido, Angel, Belda-Iniesta, Cristobal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019209/
https://www.ncbi.nlm.nih.gov/pubmed/35582274
http://dx.doi.org/10.20517/cdr.2019.61
_version_ 1784689205674246144
author Rodriguez-Pascual, Jesus
Ayuso-Sacido, Angel
Belda-Iniesta, Cristobal
author_facet Rodriguez-Pascual, Jesus
Ayuso-Sacido, Angel
Belda-Iniesta, Cristobal
author_sort Rodriguez-Pascual, Jesus
collection PubMed
description Recent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some patients are primary unresponsive or develop ulterior resistance to these family of drugs. This review aims to update the basic molecular mechanism of resistance as well as the current strategies for checkpoint inhibitor selection in order to propose new approaches to individualize the use of these novel therapies.
format Online
Article
Text
id pubmed-9019209
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-90192092022-05-16 Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies Rodriguez-Pascual, Jesus Ayuso-Sacido, Angel Belda-Iniesta, Cristobal Cancer Drug Resist Review Recent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some patients are primary unresponsive or develop ulterior resistance to these family of drugs. This review aims to update the basic molecular mechanism of resistance as well as the current strategies for checkpoint inhibitor selection in order to propose new approaches to individualize the use of these novel therapies. OAE Publishing Inc. 2019-12-19 /pmc/articles/PMC9019209/ /pubmed/35582274 http://dx.doi.org/10.20517/cdr.2019.61 Text en © The Author(s) 2019. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Rodriguez-Pascual, Jesus
Ayuso-Sacido, Angel
Belda-Iniesta, Cristobal
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
title Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
title_full Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
title_fullStr Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
title_full_unstemmed Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
title_short Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
title_sort drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019209/
https://www.ncbi.nlm.nih.gov/pubmed/35582274
http://dx.doi.org/10.20517/cdr.2019.61
work_keys_str_mv AT rodriguezpascualjesus drugresistanceincancerimmunotherapynewstrategiestoimprovecheckpointinhibitortherapies
AT ayusosacidoangel drugresistanceincancerimmunotherapynewstrategiestoimprovecheckpointinhibitortherapies
AT beldainiestacristobal drugresistanceincancerimmunotherapynewstrategiestoimprovecheckpointinhibitortherapies

Ejemplares similares